LabStyle Innovations to Report New Data at Diabetes Technology Meeting On October 22 and 23, 2015
Oct 15, 2015
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today announced Dr. Paul Rosman, who serves on the Company's Scientific Advisory Board, will present a study titled, "Performance of a Smart Phone Linked Blood Glucose Assessment Platform," at the 15th Annual Diabetes Technology Meeting in Bethesda, Maryland. The poster will be presented on Thursday, October 22, 2015 from 4:00pm to 6:30pm and on Friday, October 23, from 4:45pm to 7:15pm.
The poster presentation will include new data regarding the glucose measurement and monitoring precision of the Dario, an all-in-one blood glucose meter, smart phone application (iOS & Android), website application and treatment tool to support more proactive and better informed decisions by patients, doctors and healthcare systems.
The Diabetes Technology Meeting's goal is to assemble technology developers and users to facilitate creation of new and cost-effective tools to help people with diabetes. The meeting will particularly emphasize original data. Last year's meeting in Bethesda, Maryland brought together over 450 clinicians and scientists from 24 countries to focus on applying science and technology to fight diabetes.
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB: DRIO) develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario™ personalized smart meter. Dario™ received CE mark certification in September 2013 and began a world rollout in select countries in December 2013. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario™ smart meter (Dario™ Blood Glucose Monitoring System) in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information: http://www.mydario.com and http://mydario.investorroom.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
For further information: .